203 related articles for article (PubMed ID: 33384420)
21. Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond.
Stainczyk SA; Westermann F
Int J Cancer; 2022 Mar; 150(6):903-915. PubMed ID: 34636058
[TBL] [Abstract][Full Text] [Related]
22. Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers.
Walsh KM; Whitehead TP; de Smith AJ; Smirnov IV; Park M; Endicott AA; Francis SS; Codd V; ; Samani NJ; Metayer C; Wiemels JL
Carcinogenesis; 2016 Jun; 37(6):576-582. PubMed ID: 27207662
[TBL] [Abstract][Full Text] [Related]
23. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
[TBL] [Abstract][Full Text] [Related]
24. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
[TBL] [Abstract][Full Text] [Related]
25. Genetics and genomics of neuroblastoma.
Capasso M; Diskin SJ
Cancer Treat Res; 2010; 155():65-84. PubMed ID: 20517688
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
28.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
29. Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes.
Khan FH; Pandian V; Ramraj S; Natarajan M; Aravindan S; Herman TS; Aravindan N
BMC Cancer; 2015 Jul; 15():514. PubMed ID: 26159519
[TBL] [Abstract][Full Text] [Related]
30. ARID1B alterations identify aggressive tumors in neuroblastoma.
Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
[TBL] [Abstract][Full Text] [Related]
31. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
32. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.
Esposito MR; Binatti A; Pantile M; Coppe A; Mazzocco K; Longo L; Capasso M; Lasorsa VA; Luksch R; Bortoluzzi S; Tonini GP
Int J Cancer; 2018 Nov; 143(10):2525-2536. PubMed ID: 29992558
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions.
Buckley PG; Das S; Bryan K; Watters KM; Alcock L; Koster J; Versteeg R; Stallings RL
Int J Cancer; 2011 May; 128(10):2296-305. PubMed ID: 20669225
[TBL] [Abstract][Full Text] [Related]
34. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.
Deyell RJ; Attiyeh EF
Cancer Genet; 2011 Mar; 204(3):113-21. PubMed ID: 21504710
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
36. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
Wei JS; Johansson P; Chen L; Song YK; Tolman C; Li S; Hurd L; Patidar R; Wen X; Badgett TC; Cheuk AT; Marshall JC; Steeg PS; Vaqué Díez JP; Yu Y; Gutkind JS; Khan J
PLoS One; 2013; 8(10):e77731. PubMed ID: 24147068
[TBL] [Abstract][Full Text] [Related]
37. Genetic stratification of neuroblastoma for treatment tailoring.
Jeison M; Yaniv I; Ash S
Future Oncol; 2011 Sep; 7(9):1087-99. PubMed ID: 21919696
[TBL] [Abstract][Full Text] [Related]
38. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Sausen M; Leary RJ; Jones S; Wu J; Reynolds CP; Liu X; Blackford A; Parmigiani G; Diaz LA; Papadopoulos N; Vogelstein B; Kinzler KW; Velculescu VE; Hogarty MD
Nat Genet; 2013 Jan; 45(1):12-7. PubMed ID: 23202128
[TBL] [Abstract][Full Text] [Related]
39. Telomere length is a prognostic factor in neuroblastoma.
Ohali A; Avigad S; Ash S; Goshen Y; Luria D; Feinmesser M; Zaizov R; Yaniv I
Cancer; 2006 Sep; 107(6):1391-9. PubMed ID: 16917952
[TBL] [Abstract][Full Text] [Related]
40. The genomic profile of parathyroid carcinoma based on whole-genome sequencing.
Hu Y; Zhang X; Wang O; Bi Y; Xing X; Cui M; Wang M; Tao W; Liao Q; Zhao Y
Int J Cancer; 2020 Nov; 147(9):2446-2457. PubMed ID: 32574388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
